Post-Kidney Transplant Adverse Outcomes Increased With BMI-BSA Obesity
By Elana Gotkine HealthDay Reporter
TUESDAY, May 27, 2025 -- Combined body mass index (BMI)-body surface area (BSA) obesity is associated with an increased risk for post-kidney transplant (KT) adverse outcomes, according to a study published online May 21 in Transplantation Direct.
Roxaneh Zaminpeyma, from Dalhousie University in Halifax, Nova Scotia, Canada, and colleagues examined post-KT adverse outcomes associated with obesity, defined using combined BMI-BSA parameters, in a cohort of adult KT recipients across the United States.
A total of 242,432 patients were included in the final study: 32.0 and 28.6 percent had obesity based on BMI and BSA, respectively. The researchers found that the adjusted risk for death-censored graft loss, all-cause graft loss, and delayed graft function was greatest when both BMI and BSA indicated obesity compared with nonobese BMI and BSA (adjusted hazard ratios, 1.23, 1.09, and 1.58, respectively); the risk was significantly greater than when BMI and BSA were discordant.
"Patients with discordance between obesity-defined BMI and BSA are at significantly lower risk than those categorized as obese by both BMI and BSA metrics," the authors write. "Combined BMI-BSA-defined obesity should be considered when defining obesity-related risk at the time of kidney transplantation."
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
ENDO: Superior Weight Loss Seen With Tirzepatide and Menopausal Hormone Therapy Use
TUESDAY, July 15, 2025 -- In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is associated with superior weight loss...
Cell Therapy MDR-101 Produces Functional Immune Tolerance in Kidney Transplant Recipients
TUESDAY, July 15, 2025 -- Kidney transplant recipients receiving the investigational cellular product MDR-101 achieved functional immune tolerance for more than two years...
Certain Factors May Predict Weight Fluctuations After GLP-1 Receptor Agonist Treatment
TUESDAY, July 15, 2025 -- For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.